Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 33Cr 29Cr 27Cr 25Cr 47Cr 3.15TCr 48Cr 320.64Cr 124.69Cr 1.55TCr 124.48Cr 121.78Cr 5.37TCr P/E 2026 *
-19x
P/E 2027 * -14.5x
Enterprise Value 33Cr 29Cr 27Cr 25Cr 47Cr 3.15TCr 48Cr 320.64Cr 124.69Cr 1.55TCr 124.48Cr 121.78Cr 5.37TCr EV / Sales 2026 *
18.5x
EV / Sales 2027 * 18.3x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.75%
1 week+0.76%
Current month+0.76%
1 month+9.09%
3 months-13.16%
6 months-27.87%
Current year-20.96%
1 week 1.29
Extreme 1.29
1.38
1 month 1.18
Extreme 1.18
1.38
Current year 1.18
Extreme 1.18
1.98
1 year 0.93
Extreme 0.9296
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.8
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 17/09/2018
Director of Finance/CFO 50 14/11/2022
Chief Operating Officer - 01/12/2010
Director TitleAgeSince
Director/Board Member 60 01/07/2009
Director/Board Member 54 17/09/2018
Director/Board Member 68 11/04/2014
Date Insider Type Main position Quantity % Market Cap.
01/07Free

Director

1,25,000 0.0501%
01/07Free

Director

1,25,000 0.0501%
01/07Free

Director

1,25,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%+0.76%+38.89%-3.65% 33Cr
-1.03%+5.24%+2.94%+9.41% 5.03TCr
+0.25%+1.70%+419.39%+621.71% 4.04TCr
+1.10%+7.77%+28.18%-3.96% 3.44TCr
-0.16%+8.42%+28.20%+63.00% 3.44TCr
+1.31%-0.56%+5.12%+33.90% 2.63TCr
-0.35%+0.09% - - 1.66TCr
-3.33%+3.15%+71.30%+131.94% 1.61TCr
+0.32%+1.09%+13.28%+21.98% 1.37TCr
+3.79%+8.88%+106.63%+106.63% 1.37TCr
Average +0.16%+3.12%+79.33%+109.00% 2.46TCr
Weighted average by Cap. +0.17%+4.09%+95.67%+141.08%

Financials

2026 *2027 *
Net sales 1.79Cr 1.57Cr 1.45Cr 1.34Cr 2.55Cr 170.24Cr 2.59Cr 17Cr 6.75Cr 84Cr 6.73Cr 6.59Cr 290.4Cr 1.81Cr 1.58Cr 1.46Cr 1.35Cr 2.57Cr 171.72Cr 2.61Cr 17Cr 6.8Cr 85Cr 6.79Cr 6.65Cr 292.92Cr
Net income -2.38Cr -2.08Cr -1.92Cr -1.78Cr -3.38Cr -225.77Cr -3.43Cr -23Cr -8.95Cr -111.42Cr -8.93Cr -8.74Cr -385.12Cr -3.17Cr -2.77Cr -2.55Cr -2.37Cr -4.49Cr -300.48Cr -4.57Cr -31Cr -12Cr -148.3Cr -12Cr -12Cr -512.57Cr
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
08/26/08 $1.320 -0.75% 6,79,860
06/26/06 $1.330 -1.48% 8,42,935
02/26/02 $1.350 +3.85% 7,24,037
01/26/01 $1.300 -0.76% 7,75,272
30/26/30 $1.310 -2.96% 8,65,791
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.330USD
Average target price
5.500USD
Spread / Average Target
+313.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock